Biotech Values

[DewDiligence]

NVS, PFE submit BLAs for competing meningococcal-B vaccines:

http://finance.yahoo.com/news/novartis-submits-application-fda-meningitis-120000126.html (NVS PR)

http://finance.yahoo.com/news/pfizer-announces-submission-biologics-license-120000202.html (PFE PR)

NVS’ vaccine is called Bexsero and is already approved in the EU and various other countries. Pursuant to NVS’ recent multifaceted asset transfer with GSK announced in April (#msg-100909502), GSK will presumably take over the commercialization of Bexsero once the transaction closes. Bexsero has FDA BTD status. One analyst has projected worldwide peak annual sales of about $1.5B (#msg-81579409).

PFE’s vaccine is called LP2086 (or rLP2086) and it too has BTD status (#msg-99170995).

See #msg-79734337 for background info on meningococcal-B vaccines.